SEATTLE, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today that the new Medicare Clinical Laboratory Fee Schedule (CLFS) rate for its next-generation sequencing (NGS)-based clonoSEQ® test for minimal – or measurable – residual disease (MRD) assessment is now in effect as of January 1, 2025. The CL ...

SEATTLE, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Adaptive Biotechnologies’ management is scheduled to present on Tuesday, January 14th at 5:15 p.m. Pacific Time / 8:15 p.m. Easter ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Adaptive Biotechnologies (ADPT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Adaptive Biotechnologies is one of 1022 companies in the Medical group. The Medical group currently sits at #3 within the Zacks S ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Today, we are putting Adaptive Biotechnologies Corporation (NASDAQ: ADPT ) in the spotlight for the first time in nine months. In our last article on this diagnostic concern, we pa ...

Adaptive Biotechnologies (ADPT) closed the last trading session at $5.58, gaining 20.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $7.33 indicates a 31.4% upside potential.The average comprises six short-term price targets ranging from a low of $5 to a high of $10, with a standard deviation of $1.63. While the lowest estimate indicates a decline of 10.4% from the current price ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Karina Calzadilla - Head of IR Chad Robins - CEO and Co-Founder Kyle Piskel - CFO Susan Bobulsky - Chief Commercial Officer Conference Call Participants Dan Brennan - TD Cowen Mark Massaro - BTIG Matt Sykes - Goldman Sachs Maggie Boeye - William Blair Corey Rosenbaum - Scotiabank Operator Good day, and welcome to Adaptive Biotechnologies Third Quarter Financial Results [Operat ...

For the quarter ended September 2024, Adaptive Biotechnologies (ADPT) reported revenue of $46.44 million, up 22.5% over the same period last year. EPS came in at -$0.22, compared to -$0.35 in the year-ago quarter.The reported revenue represents a surprise of +14.41% over the Zacks Consensus Estimate of $40.59 million. With the consensus EPS estimate being -$0.30, the EPS surprise was +26.67%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they comp ...

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 26.67%. A quarter ago, it was expected that this life-sciences research company would post a loss of $0.32 per share when it actually produced a loss of $0.26, delivering a surprise of 18.75%.Over the last four qu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-09 ...

EXHIBIT 99.1 Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results SEATTLE, Nov. 07, 2024 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2024. "Our focus on execution and disciplined capital allocation are drivin ...